@article {MORITZ3631, author = {JENNIFER MORITZ and THOMAS BAUERNHOFER and SEBASTIAN MANNWEILER and TANJA LANGSENLEHNER and KARL PUMMER and NADIA DANDACHI and MARTIN PICHLER}, title = {Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients}, volume = {34}, number = {6}, pages = {3631--3638}, year = {2020}, doi = {10.21873/invivo.12209}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Carboplatin-containing treatment regimens demonstrate moderate efficacy in metastatic castration-resistant prostate cancer (mCRPC). In this study, we retrospectively analyzed the efficacy of carboplatin in relation to blood-based parameters. Patients and Methods: A retrospective chart review was performed for 20 patients with mCRPC who received carboplatin in a single center. Results: Median overall survival was 3.8 months (95\%CI=1.5-7.1), median progression-free survival was 1.7 months. We observed two partial remissions (PR, 10\%), four stable diseases (SD, 20\%) and 14 disease progressions (PD, 70\%), resulting in a clinical benefit rate of 30\%. A doubling of NSE (neurone specific enolase) values was associated with a 19\% absolute higher response rate (95\%CI=14-23, p=0.027). All other laboratory parameters failed as predictive markers of response to carboplatin. In univariate Cox regression analysis, only NSE was significantly associated with impaired PFS (HR=0.7, 95\%CI=0.56-0.96, p=0.030). Conclusion: Carboplatin showed moderate efficacy against mCRPC in this unselected population of patients and NSE levels may help to predict the success of this treatment.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/34/6/3631}, eprint = {https://iv.iiarjournals.org/content/34/6/3631.full.pdf}, journal = {In Vivo} }